These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37883001)

  • 21. Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes.
    Nunoi K; Sato Y; Kaku K; Yoshida A; Suganami H
    Endocrinol Diabetes Metab; 2018 Apr; 1(2):e00015. PubMed ID: 30815551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
    Neuen BL; Heerspink HJL; Vart P; Claggett BL; Fletcher RA; Arnott C; de Oliveira Costa J; Falster MO; Pearson SA; Mahaffey KW; Neal B; Agarwal R; Bakris G; Perkovic V; Solomon SD; Vaduganathan M
    Circulation; 2024 Feb; 149(6):450-462. PubMed ID: 37952217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal Protection and Safety of Sodium-glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
    Zhou T; Yao K; Xie Y; Lin Y; Wang J; Chen X
    Curr Pharm Des; 2023; 29(21):1659-1670. PubMed ID: 37537933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenosine/adenosine type 1 receptor signaling pathway did not play dominant roles on the influence of sodium-glucose cotransporter 2 inhibitor in the kidney of bovine serum albumin-overloaded streptozotocin-induced diabetic mice.
    Shimada K; Kanasaki K; Kato M; Ogura Y; Takagaki Y; Monno I; Hirai T; Kitada M; Koya D
    J Diabetes Investig; 2022 Jun; 13(6):955-964. PubMed ID: 35098679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
    Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
    Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis.
    Ma C; Li X; Li W; Li Y; Shui F; Zhu P
    Int Urol Nephrol; 2023 Dec; 55(12):3167-3174. PubMed ID: 37046125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urine Albumin-Creatinine Ratio Variability in People With Type 2 Diabetes: Clinical and Research Implications.
    Rasaratnam N; Salim A; Blackberry I; Cooper ME; Magliano DJ; van Wijngaarden P; Varadarajan S; Sacre JW; Shaw JE
    Am J Kidney Dis; 2024 Jul; 84(1):8-17.e1. PubMed ID: 38551531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
    Ferreira JP; Zannad F; Butler J; Filippatos G; Pocock SJ; Brueckmann M; Steubl D; Schueler E; Anker SD; Packer M
    JAMA Cardiol; 2022 Nov; 7(11):1148-1159. PubMed ID: 36129693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors.
    Katano S; Yano T; Kouzu H; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Ohori K; Nagano N; Fujito T; Nishikawa R; Ohwada W; Katayose M; Sato T; Kuno A; Furuhashi M
    Cardiovasc Diabetol; 2022 Dec; 21(1):285. PubMed ID: 36539818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Sensor-Augmented Pump Treatment Versus Multiple Daily Injections on Albuminuria: A 1-Year Randomized Study.
    Rosenlund S; Hansen TW; Rossing P; Andersen S
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4181-8. PubMed ID: 26390102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
    Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the utility of the urine dipstick and urine protein-to-creatinine ratio for predicting microalbuminuria in patients with non-diabetic lifestyle-related diseases -a comparison with diabetes.
    Ogi M; Seto T; Wakabayashi Y
    BMC Nephrol; 2022 Nov; 23(1):377. PubMed ID: 36434544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A protocol for systematic review and meta-analysis.
    Yu B; Dong C; Hu Z; Liu B
    Medicine (Baltimore); 2021 Feb; 100(8):e24655. PubMed ID: 33663074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.
    Shimohata H; Iwaki Y; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
    Int Urol Nephrol; 2022 Aug; 54(8):1907-1914. PubMed ID: 34843041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study.
    Fu WJ; Xiong SL; Fang YG; Wen S; Chen ML; Deng RT; Zheng L; Wang SB; Pen LF; Wang Q
    Endocrine; 2012 Feb; 41(1):82-8. PubMed ID: 21779943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction.
    Sato S; Takayanagi K; Shimizu T; Kanozawa K; Iwashita T; Hasegawa H
    Eur J Med Res; 2022 Aug; 27(1):140. PubMed ID: 35933386
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.